Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ASPH | Q12797 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863152 | 0.84 | AGBL2 (0.51) | AGBL2HCAR2GABRPGABRDGABRA1 | |
| SCHEMBL17668865 | 0.82 | AGBL2 (0.50) | AGBL2HCAR2GABRPGABRDGABRA1 | |
| SCHEMBL26928475 | 0.82 | AGBL2 (0.50) | AGBL2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2592299 | 0.79 | AGBL2 (0.47) | AGBL2KDM4EBACE1ALDH1A1 | |
| SCHEMBL107357 | 0.79 | HCAR2 (0.45) | AGBL2HCAR2KDM4EASPHKDM8 | |
| SCHEMBL7190906 | 0.79 | HCAR2 (0.45) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL8566219 | 0.78 | KDM4E (0.46) | AGBL2HCAR2GABRPGABRDGABRA1 | |
| SCHEMBL16011625 | 0.78 | CYP3A4 (0.44) | AGBL2HCAR2GABRPGABRDGABRA1 | |
| SCHEMBL15991202 | 0.78 | SPR (0.48) | AGBL2HCAR2KDM4EASPHKDM8 | |
| SCHEMBL9508588 | 0.78 | HCAR2 (0.44) | HCAR2GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | claimed |
| US-9605006-B2 | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines | HOFFMANN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | claimed |
| EP-3083644-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. Hoffmann-La Roche AG (CH) | 2016-10-26 | — | — | EP | claimed |
| CN-105683199-A | 5-aryl-1-imino-1-oxo- [1,2,4] thiadiazines | 豪夫迈·罗氏有限公司 | 2016-06-15 | — | — | CN | claimed |
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | claimed |
| WO-2015091595-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2663559-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | claimed |
| WO-2012095463-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-4434980-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3481805-A1 | PROCESS FOR PREPARING HALOGENATED PYRIDINE DERIVATIVES | Bayer CropScience Aktiengesellschaft (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| WO-2011138293-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281449-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | GRIK5, OTC, GRIN2C | AGBL2 3457/4885HCAR2 757/4885GABRP 445/4885 |
| US-20160318952-A1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | BACE1, BACE2, PSEN1 | AGBL2 745/4885HCAR2 2932/4885GABRP 1776/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | AGBL2 72/4885HCAR2 1261/4885GABRP 597/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | AGBL2 94/4885HCAR2 504/4885GABRP 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.